Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.40 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | CDC25B | P30305 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | GLS | O94925 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8577340 | 0.81 | CASP3 (0.43) | CASP3POLBALDH1A1TTRCES1 | |
| SCHEMBL19533850 | 0.81 | CASP3 (0.43) | CASP3POLBALDH1A1TTRCES1 | |
| SCHEMBL8577334 | 0.81 | CASP3 (0.43) | CASP3POLBALDH1A1TTRCES1 | |
| SCHEMBL31377013 | 0.81 | CASP3 (0.43) | CASP3POLBALDH1A1TTRCES1 | |
| SCHEMBL30559874 | 0.81 | CASP3 (0.43) | CASP3POLBALDH1A1TTRCES1 | |
| SCHEMBL35297 | 0.80 | ALDH1A1 (0.48) | CASP3POLBALDH1A1CYP1A2EHMT2 | |
| SCHEMBL30124938 | 0.80 | ALDH1A1 (0.48) | CASP3POLBALDH1A1CYP1A2EHMT2 | |
| SCHEMBL29372938 | 0.80 | ALDH1A1 (0.48) | CASP3POLBALDH1A1CYP1A2EHMT2 | |
| SCHEMBL2910409 | 0.80 | POLB (0.43) | CASP3POLBALDH1A1CES1CYP1A2 | |
| SCHEMBL20954062 | 0.79 | POLB (0.46) | CASP3POLBALDH1A1CES1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118047783-A | Substituted triazole compound and preparation method and application thereof | 山东大学 | 2024-05-17 | — | — | CN | claimed |
| CN-114591281-B | Preparation method of allyl alcohol compound | 河南师范大学 | 2023-09-29 | — | — | CN | claimed |
| CN-114591281-A | Preparation method of allyl alcohol compound | 河南师范大学 | 2022-06-07 | — | — | CN | claimed |
| US-20100298370-A1 | BENZOTHIAZOLYL THIENOPYRIDINE DERIVATIVES AND USES THEREOF | RIMONYX PHARMACEUTICALS LTD. (IL) | 2010-11-25 | — | — | US | claimed |
| WO-2008020438-A2 | BENZOTHIAZOLYL THIENOPYRIDINE DERIVATIVES AND USES THEREOF | RIMONYX PHARMACEUTICALS LTD (IL) | 2008-02-21 | — | — | WO | claimed |
| EP-1309589-A2 | UREA COMPOUNDS AND METHODS OF USES | Amgen Inc. (US) | 2003-05-14 | — | — | EP | claimed |
| EP-0865339-B1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARM (GB) | 2003-01-22 | — | — | EP | claimed |
| US-20020173507-A1 | Urea compounds and methods of uses | AMGEN INC. | 2002-11-21 | — | — | US | claimed |
| WO-2002014311-A2 | UREA COMPOUNDS AND METHODS OF USES | AMGEN INC. (US) | 2002-02-21 | — | — | WO | claimed |
| US-6103739-A | BONE RESORPTION; ANTIINFLAMMATORY AGENTS, SKIN DISORDERS; ANTITUMOR-CARCINOGENIC AND METASTASES AGENTS; ANGIOGENESIS INHIBITORS; ANTIARRITHIC AGENTS; RHEUMATOID DISEASES; OSTEOARTHRITIS, PERIODONTITIS, GINGIVITIS AND CORNEAL ULCERS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-08-15 | — | — | US | claimed |
| EP-0944597-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-09-29 | — | — | EP | claimed |
| EP-0865339-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-09-23 | — | — | EP | claimed |
| WO-1998023588-A9 | METALLOPROTEINASE INHIBITORS | — | 1998-09-17 | — | — | WO | claimed |
| WO-1998023588-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-06-04 | — | — | WO | claimed |
| WO-1997003783-A9 | METALLOPROTEINASE INHIBITORS | — | 1997-04-03 | — | — | WO | claimed |
| WO-1997003783-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1997-02-06 | — | — | WO | claimed |
| EP-0046289-B1 | SUBSTITUTED ENANTHOLACTAM DERIVATIVES AS ANTIHYPERTENSIVES, A PROCESS FOR PREPARING AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM, AND INTERMEDIATES | MERCK & CO. INC. (US) | 1985-11-27 | — | — | EP | claimed |
| CN-118047783-A | Substituted triazole compound and preparation method and application thereof | 山东大学 | 2024-05-17 | — | — | CN | disclosed |
| US-3992388-A | INTERMEDIATE FOR SULFAMYLUREA HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1976-11-16 | — | — | US | disclosed |
| US-3933830-A | FROM 4-(2-PYRIDYLAMIDOETHYL) PYRIDINES REDUCED WITH HYDROGEN AND A NOBLE METAL CATALYST | PFIZER INC. (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173507-A1 | Urea compounds and methods of uses | SLC14A1, UMPS, BAX | CASP3 8/4885POLB 1093/4885ALDH1A1 865/4885 |
| US-20100298370-A1 | BENZOTHIAZOLYL THIENOPYRIDINE DERIVATIVES AND USES THEREOF | HPSE, HDGF, HPGDS | CASP3 1345/4885POLB 2874/4885ALDH1A1 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.